Immuneering Corporation (IMRX) vs Palisade Bio, Inc. (PALI)
Immuneering Corporation and Palisade Bio, Inc. are both Biotechnology companies. Immuneering Corporation and Palisade Bio, Inc. are of similar size ($280.8M and $273.6M). Immuneering Corporation has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against −84.8%. Immuneering Corporation has the higher net margin (0.00% vs −4,230.6%) and the lower return on invested capital (−97.1% vs 0.00%). Across the 16 metrics below, Palisade Bio, Inc. leads on 10 and Immuneering Corporation on 6.
Valuation
Profitability
| Metric | IMRX | PALI | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 95.63% | 65.16% |
| Operating margin | 0.00% | (4,681.99%) | 0.00% |
| Net margin | 0.00% | (4,230.60%) | 0.00% |
| Free cash flow margin | 0.00% | (2,409.27%) | 0.00% |
| Return on equity | (52.15%) | (51.37%) | (57.72%) |
| Return on assets | (47.31%) | (47.68%) | (49.22%) |
| Return on invested capital | (97.14%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack